The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > COMMENTARY
COMMENTARY
- First SGLT-2 Inhibitor Set to Debut Next April; Curtain Rising on “Unprecedentedly Competitive” Market
December 18, 2013
- Bearing “Edo” in Its Name, Japan-Originated Edoxaban Set to Challenge Rival Anticoagulants in World Market
December 6, 2013
- MHLW Shocks Generic Drug Industry by Proposing “50% Rule,” Expansion of Uniform Pricing
November 19, 2013
- Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions
November 13, 2013
- Interim Report of Diovan Committee Raises Further Questions
October 15, 2013
- Remicade Biosimilar Debut Awaited in FY2014; Good Opportunity to Revisit Healthcare Finance?
October 4, 2013
- Comprehensive Review of Package Inserts to Begin with Effort to Identify Inconsistencies Between Inserts for Similar Drugs
August 27, 2013
- Transparency Guidelines Go Live, Will It Help Pharmas Win Public Trust?
August 2, 2013
- Overseas Outlook Will Be Essential to Survival and Progress of Domestic CROs
June 24, 2013
- PMDA’s Seriousness About Becoming a Leading Global Regulatory Authority to Be Tested
May 30, 2013
- Beyond Risk Management: RMPs Provide Opportunity for Post-Marketing Drug Development and Product Differentiation
May 8, 2013
- Iressa Cases Signal Risks Hiding in Daily Clinical Practices
April 22, 2013
- Will Drugs that Fight Cancer Stem Cells Succeed? Domestic Clinical Trial by DSP on the Horizon
March 15, 2013
- Gov’t, Industry to Support Developing Countries through Development of Drugs for Infectious Diseases; Hoping to Secure Future Business Opportunities as Well
February 27, 2013
- What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
- Hot Products in 2013: New Drugs Likely to Jolt RA Treatment, Anticoagulant Markets
January 8, 2013
- Counterfeit Drugs: Risks Lurking in Globalization
December 28, 2012
- Can Japan Craft Its Own “Compassionate Use” System without Spoiling Drug Makers’ Development Drives?
December 7, 2012
- Recent Announcements of Suspended Product Supplies Highlight Supply Risks Faced by Generic Drug Industry
November 27, 2012
- Will Integration of Domestic Makers Be Enough for Sustainable Plasma Fractionation Operations?
November 16, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…